Abstract
Malignant solid tumors have been traditionally treated utilizing cytotoxic chemotherapies, which work against rapidly multiplying tumors. The current response evaluation in solid tumor is based on the Response Evaluation Criteria in Solid Tumors (RECIST). This method relies mainly on computerized tomography (CT scans) and other imaging modalities by which the diameter of tumors is taken into consideration to assess response to therapy. Recent years have witnessed the introduction of a series of new signal transduction inhibitors in the management of metastatic RCC. Stable disease (SD) is more frequently seen with morphologic lesion changes such as, change in attenuation, pattern of intratumoral enhancement / necrosis and cavitation, all of which pose a challenge for the investigator in the accurate assessment of response to therapy. This article attempts to introduce the reader to various alternate concepts of monitoring response following biologic therapy and offers a detailed analysis of a few lesions.
Keywords: Renal cell carcinoma, response evaluation, radiological evaluation, functional imaging
Reviews on Recent Clinical Trials
Title: Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors
Volume: 5 Issue: 2
Author(s): Saby George, Shetal N. Shah and Ronald M. Bukowski
Affiliation:
Keywords: Renal cell carcinoma, response evaluation, radiological evaluation, functional imaging
Abstract: Malignant solid tumors have been traditionally treated utilizing cytotoxic chemotherapies, which work against rapidly multiplying tumors. The current response evaluation in solid tumor is based on the Response Evaluation Criteria in Solid Tumors (RECIST). This method relies mainly on computerized tomography (CT scans) and other imaging modalities by which the diameter of tumors is taken into consideration to assess response to therapy. Recent years have witnessed the introduction of a series of new signal transduction inhibitors in the management of metastatic RCC. Stable disease (SD) is more frequently seen with morphologic lesion changes such as, change in attenuation, pattern of intratumoral enhancement / necrosis and cavitation, all of which pose a challenge for the investigator in the accurate assessment of response to therapy. This article attempts to introduce the reader to various alternate concepts of monitoring response following biologic therapy and offers a detailed analysis of a few lesions.
Export Options
About this article
Cite this article as:
George Saby, N. Shah Shetal and M. Bukowski Ronald, Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors, Reviews on Recent Clinical Trials 2010; 5 (2) . https://dx.doi.org/10.2174/157488710791233635
DOI https://dx.doi.org/10.2174/157488710791233635 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry eBook Review (Review of The Bentham e-Book entitled “Anti-angiogenesis drug discovery and development- Volume 2” edited by Atta-ur-Rahman and M Iqbal Choudhary)
Current Vascular Pharmacology Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Birt-hogg-Dubé Syndrome Incidentally Identified in a Potential Liver Donor
Current Medical Imaging Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Recent Patents and Advances in Hepatocyte-Like Cells Differentiation by Perinatal Stem Cells
Recent Patents on Regenerative Medicine